CSBC Pharma (01093.HK) announced that its first hybrid CAR-T cell mRNA-LNP injection (SYS6020) has been approved by the China National Medical Products Administration for clinical trials in China.

It is reportedly the world's first mRNA-LNP-based cell therapy product approved for clinical trials. By expressing CAR that specifically recognizes BCMA antigens, it targets and kills BCMA positive cells in the patient's body to achieve the treatment purpose.

CSBC Pharma also stated that the approved clinical indication for this product is multiple myeloma (MM). In addition, the product may potentially be used to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG).